Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Islatravir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312706063/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials

    20 Dec 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/mercks-hiv-combo-treatment-meets-bar-viral-suppression-pair-phase-3-studies

    FIERCE BIOTECH
    20 Dec 2024
    Share Share
    Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
    Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks

    22 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-gilead-long-acting-oral-combo-suppresses-hiv-48-weeks-setting-stage-pivotal-program

    FIERCE BIOTECH
    22 Oct 2024
    Share Share
    Merck-Gilead's weekly HIV combo maintains viral suppression
    Merck-Gilead's weekly HIV combo maintains viral suppression

    07 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-gileads-weekly-hiv-combo-maintains-viral-suppression-its-early-days-primary-endpoint

    FIERCE BIOTECH
    07 Mar 2024
    Share Share
    Merck Opens Enrollment in PIII with Islatravir in Combination with Doravirine
    Merck Opens Enrollment in PIII with Islatravir in Combination with Doravirine

    22 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230222005448/en

    BUSINESSWIRE
    22 Feb 2023
    Share Share
    Merck’s HIV pipeline shifts as islatravir PrEP program is discontinued
    Merck’s HIV pipeline shifts as islatravir PrEP program is discontinued

    29 Sep 2022

    // Adam Zamecnik PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/mercks-hiv-pipeline-shifts-as-prep-program-discontinues/

    Adam Zamecnik PHARMACEUTICAL-TECHNOLOGY
    29 Sep 2022
    Share Share